Rosetta Genomics Ltd. (ROSG) announced Wednesday morning that Novitas informed the company that it plans to cover the company's miRview mets² assay for all Medicare beneficiaries. MiRview mets² accurately identifies the primary tumor of origin in primary and metastatic cancer.
Rosetta Genomics gapped up Wednesday and rose steadily throughout the first hour of trade. The stock finished up by 3.37 at $4.99 on the highest volume of the year and broke out to over a one-month high.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.